A Phase II Study of Mismatched Unrelated Donor Stem Cell Transplantation in People with Blood Cancers

Share
Print

Full Title

ACCESS: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies (NMDP)

Purpose

The transplantation of stem cells from a donor whose immune system matches that of the recipient is one way to treat blood cancers. Some patients who need a transplant do not have a matched donor. In this case, a related or unrelated person can be the stem cell donor, even if their immune system is only partially matched. In this study, researchers are assessing a transplant approach for patients with blood cancers using a partially matched, unrelated stem cell donor.

Another study showed that transplantation in adults with a mismatched unrelated donor could work using cells from the donor’s bone marrow. This study is being done to perform transplantation in adults using stem cells from a mismatched unrelated donor’s blood, rather than from their bone marrow. Doctors are trying to learn how to give these transplants so that more people who need a transplant are able to get one.

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have a blood cancer such as acute myeloid leukemia, acute lymphoblastic leukemia, chronic leukemia, myelodysplastic syndromes, or lymphoma.
  • Participants must be candidates for stem cell transplantation and not have a matched donor who is available to donate.

For more information about this study and to ask about eligibility, please contact the office of Dr. Brian Shaffer at 646-608-3737.

Protocol

21-326

Phase

II

Investigator

Co-Investigators